Author(s):
Tarshni Murale, Jiyauddin Khan, Eva Tan Lee Yin
Email(s):
jiyauddin_khan@msu.edu.my
DOI:
10.52711/0974-360X.2025.00768 
Address:
Tarshni Murale1,3,4, Jiyauddin Khan2*, Eva Tan Lee Yin1,3
1School of Graduate Studies, Postgraduate Centre, Management and Science University, 40100 Shah Alam, Selangor Darul Ehsan, Malaysia.
2School of Pharmacy, Management and Science University, 40100 Shah Alam, Selangor Darul Ehsan, Malaysia.
3Faculty of Health and Life Sciences, Management and Science University, 40100 Shah Alam, Selangor Darul Ehsan, Malaysia.
4Research and Development Department, Pharmaniaga Research Centre Sdn Bhd, 40000 Shah Alam, Selangor Darul Ehsan, Malaysia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
Pharmaceutical scientists currently employ a range of strategies to maintain constant blood concentrations of therapeutic medications. When it comes to treating type 2 diabetes, metformin hydrochloride and gliclazide are the most recommended anti-diabetic medications. In general, to formulate a controlled-release drug hydrophilic polymers are commonly used as it is widely available and ease of its usage. In order to identify which kind of polymer is best for the release of both active components, this study employed hydrophilic and hydrophobic polymers at different concentrations. The tablets were compressed using direct compression method with a 21 mm oblong concave punches and upon compression the tablets were tested for their physical parameters such as diameter and thickness, mechanical characteristics such as hardness and friability, in-vitro drug release and drug release kinetics as per the USP and ICH guidelines. All the prepared formulations were evaluated via the in-vitro study to observe which formulations shows the highest similarity factors (f2) when compared to the Reference Product. It was obtained that F6 containing 25% of HPMC (Shin Itsu) as polymer with Metformin as the active ingredient has a similarity factor of 55.0% when tested against the Reference Product. Meanwhile, F1 containing 45% of Methocel (K100) as polymer with Gliclazide as the active ingredient has a similarity factor of 55.3% when tested against the Reference Product. This indicates that the hydrophilic polymers that were incorporated into the formulation of the two active ingredients enhanced their release yet, the brands and concentrations of these polymers differ. Final locked formula (F17) was compressed as a bilayer tablet consisting Metformin with 25% of HPMC polymer and Gliclazide with 45% of Methocel polymer, tested for in-vitro study against the Reference Product was observed to achieve a similarity factor of more than 50% for both the active ingredients. A drug-excipient compatibility study was also conducted for the finalized formula in order to ensure there are no interference between both the drugs and excipients used. The release of drug from the marketed preparation and matrix preparation (F17) was found to be a diffusion drug mechanism for Metformin and erosion drug mechanism for Gliclazide as per Korsmeyer-Peppas equation.
Cite this article:
Tarshni Murale, Jiyauddin Khan, Eva Tan Lee Yin. Comparative Study on the effect of Hydrophilic and Hydrophobic Polymers on the Dissolution Rate of Metformin-gliclazide Extended-release Bilayer Tablet. Research Journal Pharmacy and Technology. 2025;18(11):5329-6. doi: 10.52711/0974-360X.2025.00768
Cite(Electronic):
Tarshni Murale, Jiyauddin Khan, Eva Tan Lee Yin. Comparative Study on the effect of Hydrophilic and Hydrophobic Polymers on the Dissolution Rate of Metformin-gliclazide Extended-release Bilayer Tablet. Research Journal Pharmacy and Technology. 2025;18(11):5329-6. doi: 10.52711/0974-360X.2025.00768 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-30
REFERENCES:
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 (Supplement_1): S62-9. DOI: 10.2337/dc14-S081
2. Patel N, Kumar PA, Damien T, Rao BS, Kulkarni SV. Use of Hydrophilic Natural Guar Gum in Formulation of Controlled-Release Matrix Tablets of Metformin Hydrochloride and Its Comparison with Marketed Product. Research Journal of Pharmaceutical Dosage Forms and Technology. 2010; 2(2): 193-7. https://rjpdft.com/AbstractView.aspx?PID=2010-2-2-14
3. Papich MG, Lindeman C. Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision. Journal of Veterinary Diagnostic Investigation. 2018; 30(1): 113-20. https://doi.org/10.1177/1040638717742434
4. Hajare AA, Patil VA. Formulation and characterization of metformin hydrochloride floating tablets. Asian Journal of Pharmaceutical Research. 2012; 2(3): 111-7. https://asianjpr.com/AbstractView.aspx?PID=2012-2-3-6
5. Tummala S, Kumar MNS, Kumar RS, Prakash A, Mulukutla S, Raju KR. Preparation, Physicochemical Characterization, Optimization and In Vitro Comparative Evaluation of Gliclazide-Eudragit Nanoparticles and Gliclazide-Poly (lactide-co-glycolide) Nanoparticles with Marketed Products for The Treatment of Diabetes Mellitus. International Journal of Pharmaceutical Sciences Review and Research. 2014; 29(1): 289-295. https://www.globalresearchonline.net/
6. Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide: a review. Journal of Applied Pharmaceutical Science. 2011; 9: 11-9. https://japsonline.com/admin/php/uploads/253_pdf.pdf
7. Patil MB, Maru AD, Bhadane JS. Formulation and Evaluation of Sustained Release Bilayer Matrix Tablet of Glimepiride and Metformin Hydrochloride. Asian J. Res. Pharm. Sci. 2021; 11(4): 273-279. DOI: 10.52711/2231-5659.2021.00043
8. Shivhare UD, Darakh V, Mathur VB, Bhusari KP, Godbole MD. Preparation and evaluation of metformin hydrochloride microcapsules. Research Journal of Pharmacy and Technology. 2009; 2(3): 559-62. https://rjptonline.org/AbstractView.aspx?PID=2009-2-3-75
9. Khan NA, Khan A, Ullah R, Ullah M, Alotaibi A, Ullah R, Haider A. Preparation and characterization of hydrophilic polymer based sustained-release matrix tablets of a high dose hydrophobic drug. Polymers. 2022; 14(10): 1985. DOI: 10.3390/polym14101985
10. Heinz D, Amado E, Kressler J. Polyphilicity—an extension of the concept of amphiphilicity in polymers. Polymers. 2018; 10(9): 960. https://doi.org/10.3390/polym10090960
11. Jia J, Chen Z, Jiang H, Belmabkhout Y, Mouchaham G, Aggarwal H, Adil K, Abou-Hamad E, Czaban-Jóźwiak J, Tchalala MR, Eddaoudi M. Extremely hydrophobic POPs to access highly porous storage media and capturing agent for organic vapors. Chem. 2019; 10; 5(1): 180-91. doi.org/10.1016/j.chempr.2018.10.005
12. Kothawade PI, Zate SU, Gajbe JW, Rathi MN, Yewale CP, Baheti DR. Design and Evaluation of Sustained Release Matrix Tablet of Metformin Hydrochloride. Research Journal of Pharmacy and Technology. 2010; 3(2): 522-5. https://rjptonline.org/AbstractView.aspx?PID=2010-3-2-36
13. Sharma G, Verma VS, Sharma M, Chandrakar S, Gupta S, Solanki H, Dewangan K, Sahu VD, Majumdar M, Tripathi DK, Alexander A. Formulation and evaluation of extended release tablets of Diltiazem hydrochloride. Research Journal of Pharmacy and Technology. 2016; 9(7): 782-8. DOI: 10.5958/0974-360X.2016.00150.5
14. Bhangale PN, Mahajan HS, Wagh RD. Formulation and Development of Sustained Release Microspheres of Metformin Hydrochloride. Research Journal of Pharmacy and Technology. 2010; 3(1): 267-71. https://rjptonline.org/AbstractView.aspx?PID=2010-3-1-57
15. Dhavale S, Jagtap R, Kotkar T, Bhosale AV, Hardikar SR. Formulation and Evaluation of Floating Sustained Drug Delivery for Metformin HCl Using Combination of Natural and Synthetic Polymers. Research Journal of Pharmaceutical Dosage Forms and Technology. 2009; 1(3): 244-9. https://rjpdft.com/AbstractView.aspx?PID=2009-1-3-18
16. Diaz DA, Colgan ST, Langer CS, Bandi NT, Likar MD, Van Alstine L. Dissolution similarity requirements: how similar or dissimilar are the global regulatory expectations?. The AAPS Journal. 2016; 18: 15-22.doi: 10.1208/s12248-015-9830-9
17. Arafat M, Sakkal M, Yuvaraju P, Esmaeil A, Poulose V, Aburuz S. Effect of Excipients on the Quality of Drug Formulation and Immediate Release of Generic Metformin HCl Tablets. Pharmaceuticals. 2023; 16(4): 539. https://doi.org/10.3390/ph16040539
18. Manikandan M, Kannan K, Selvamuthukumar S, Manavalan R. Design, Development and Evaluation of Metformin Hydrochloride and Glimepiride Immediate Release Tablets. Research Journal of Pharmacy and Technology. 2012; 5(4): 547-52. https://rjptonline.org/HTMLPaper.aspx?Journal=Research%20Journal%20of%20Pharmacy%20and%20Technology;PID=2012-5-4-11
19. Nishanth I., Elango K., Deattu N., Stephen P. Formulation Development and Evaluation of Bilayer Tablets of Telmisartan for Immediate Release and Metformin Hydrochloride for Sustained Release. Research J. Pharma. Dosage Forms and Tech. 2013; 5(3): 139-144. https://rjpdft.com/AbstractView.aspx?PID=2013-5-3-5
20. Bhoyar PK, Biyani DM, Shahare HV, Ikhar PK, Borkar VS. Formulation and Evaluation of Taste Masked Sustained Release Dosage Form of Metformin Hydrochloride Using Indion Resin. Research J. Pharma. Dosage Forms and Tech. 2009; 1(1): 49-54. https://rjpdft.com/AbstractView.aspx?PID=2009-1-1-11
21. Jain AA, Panigrahy RN, Mahale AM. Formulation and Evaluation of Extended Release Metformin Hydrochloride Microspheres by Ionotropic Gelation Technique. Research Journal of Pharmacy and Technology. 2011; 4(7): 1055-9. https://rjptonline.org/AbstractView.aspx?PID=2011-4-7-3
22. Patil UK, Sahu R, Yadav SK. Formulation and evaluation of controlled release microspheres containing metformin hydrochloride. Research Journal of Pharmacy and Technology. 2009; 2(1): 176-9. https://rjptonline.org/AbstractView.aspx?PID=2009-2-1-89